Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1 2

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Vincristine 7Cyclophosphamide 710-propargyl-10-deazaaminopterin 7Prednisone 6Doxorubicin 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5romidepsin 3belinostat 3Gemcitabine 3liposomal doxorubicin 2duvelisib 1Vitamin B 12 1MLN 8237 1Folic Acid 1Etoposide 1E7777 fusion protein 1Decitabine 1CHOP protocol 1Brentuximab Vedotin 1Bendamustine Hydrochloride 1BAEC protocol 1Alemtuzumab 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Lymphoma, T-Cell, Peripheral × belinostat × Clear all
NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT07234162 2025-11-18

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Dizal Pharmaceuticals

Phase 3 Recruiting
218 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT06072131 2025-10-23

CRESCENDO

Acrotech Biopharma Inc.

Phase 3 Recruiting
504 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡